These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 29400284

  • 1. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K, Nakamura Y, Fujisawa Y, Endo R, Tanaka R, Ishitsuka Y, Maruyama H, Watanabe R, Okiyama N, Fujimoto M.
    Eur J Dermatol; 2018 Feb 01; 28(1):129-130. PubMed ID: 29400284
    [No Abstract] [Full Text] [Related]

  • 2. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ, Shirai K.
    J Immunother; 2019 May 01; 42(4):136-141. PubMed ID: 30933044
    [Abstract] [Full Text] [Related]

  • 3. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
    Maeda T, Hiura A, Uehara J, Toyoshima R, Nakagawa T, Yoshino K.
    Eur J Dermatol; 2021 Oct 01; 31(5):662-664. PubMed ID: 34642136
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
    Tomsitz D, Hein R, Biedermann T, Kohlmeyer J.
    J Eur Acad Dermatol Venereol; 2018 Jan 01; 32(1):e26-e28. PubMed ID: 28662283
    [No Abstract] [Full Text] [Related]

  • 5. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.
    Eur J Cancer; 2017 Nov 01; 86():37-45. PubMed ID: 28961465
    [Abstract] [Full Text] [Related]

  • 6. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
    Kuwatsuka Y, Iwanaga A, Kuwatsuka S, Okubo Y, Murayama N, Ishii N, Hashimoto T, Utani A.
    J Dermatol; 2018 Jan 01; 45(1):e21-e22. PubMed ID: 28944534
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.
    Eur J Cancer; 2019 Jul 01; 116():207-215. PubMed ID: 31212163
    [Abstract] [Full Text] [Related]

  • 9. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN, Abushukair HM, Ababneh OE, Syaj SS, Al-Horani SS, Qarqash AA, Darabseh OA, Al-Sous MM, Al-Aomar SR, Ahmed YB, Haddad R, Al Qarqaz FA.
    Clin Transl Oncol; 2021 Sep 01; 23(9):1885-1904. PubMed ID: 33877531
    [Abstract] [Full Text] [Related]

  • 10. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 01; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 11. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
    Joseph RW, Shillington AC, Lee TA, Macahilig CP, Diede SJ, Dave V, Harshaw Q, Scherrer E, Liu FX.
    J Med Econ; 2020 Feb 01; 23(2):132-138. PubMed ID: 31750751
    [Abstract] [Full Text] [Related]

  • 12. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
    Petrella TM, Robert C, Richtig E, Miller WH, Masucci GV, Walpole E, Lebbe C, Steven N, Middleton MR, Hille D, Zhou W, Ibrahim N, Cebon J.
    Eur J Cancer; 2017 Nov 01; 86():115-124. PubMed ID: 28987768
    [Abstract] [Full Text] [Related]

  • 13. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R, Otsuka A, Kaku Y, Honda T, Kabashima K.
    Eur J Dermatol; 2018 Feb 01; 28(1):84-85. PubMed ID: 29400292
    [No Abstract] [Full Text] [Related]

  • 14. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Uchi H, Fujimura T, Matsushita S, Hata H, Okuhira H, Tanaka R, Nagai K, Ishida Y, Nakamura Y, Furudate S, Yamamura K, Imafuku K, Yamamoto Y.
    J Dermatol Sci; 2018 Jan 01; 89(1):60-66. PubMed ID: 29079332
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.
    Joshi K, Atwal D, Ravilla R, Pandey Y, Yarlagadda N, Kakadia S, Makhoul I, Hutchins L, Mahmoud F.
    Perm J; 2020 Jan 01; 24():. PubMed ID: 32097116
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis.
    Yang Y, Pei J, Gao G, Yang Z, Guo S, Yue B, Qiu J.
    Oncotarget; 2016 Dec 06; 7(49):80855-80871. PubMed ID: 27764796
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
    Sato M, Uhara H, Koga H, Okuyama R.
    J Dermatol; 2018 Oct 06; 45(10):e287-e289. PubMed ID: 29655228
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.